ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 626

Ultrasound Assessment Of Both Carotid and Femoral Arteries In Patients With Systemic Lupus Erythematosus Increases Sensitivity For Detecting Asymptomatic Atherosclerosis

Sara Croca1, D.a. Isenberg2 and Anisur Rahman3, 1Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 2Centre for Rheumatology Research, University College London, London, United Kingdom, 3Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, systemic lupus erythematosus (SLE) and ultrasound

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

SLE is an independent risk factor for cardiovascular disease (CVD). Traditional risk assessment tools underestimate the actual CVD risk of these patients limiting the possibility of establishing primary prevention strategies. Vascular ultrasound (US) is an accurate, non-invasive, non-irradiating method to assess asymptomatic patients thus providing valuable insight into their real CVD risk. To our knowledge, to date only carotid US studies have been performed to assess atherosclerotic burden in patients with SLE. We propose that 4-point vascular assessment including both the carotid and femoral territories increases the sensitivity of the method and would be beneficial in assessing CVD risk in patients with SLE.

Methods: We performed US of carotid and femoral territories in 100 patients who fulfilled ACR classification criteria for SLE and had no prior diagnosis or symptoms of CVD. Intima-media thickness (IMT) of the common carotid artery (CCA) and carotid bulb were measured. Plaque and thickened IMT (>0.1cm) were defined according to the Mannheim Carotid IMT Consensus. Data on auto-antibody profile, lipids, treatment and smoking status were obtained through clinical records and patient interviews. The 10-year risk for myocardial infarction (MI) using the Framingham risk score was calculated

Results: Of the 100 asymptomatic patients, 95% were women and the overall mean age was 45.2 years (SD 12.4; range 20-66). 56 patients were Caucasian, 25 were of Afro-Caribbean-origin, 11 were Asian and 8 patients had other ethnic backgrounds (Chinese or mixed race).Only 2 had thickened IMT in the CCA but 37 had plaque. This included 14 with only carotid plaque, 7 with only femoral plaque and 16 with both. 15 had plaque in at least 3 sites. Patients with plaque were significantly older than patients without plaque at diagnosis (mean age 33 vs 27 yrs, P=0.006) and at time of scan (54 vs 40 yrs, P<0.0001) and had longer disease duration (21 vs 14 yrs, P=0.002). There were no differences in auto-antibody profile, lipids, smoking status and treatment between patients with or without plaque. The mean Framingham 10 year risk for MI for all 100 patients was <1% and there were no differences between patients with or without plaque. Interestingly, patients who had plaque on the femorals had significantly thicker carotid IMT compared to those who didn’t even in the absence of carotid plaque (p=0.015).

Conclusion: Our results confirm a high prevalence of asymptomatic atherosclerotic plaque in patients with SLE even where Framingham risk scores are low and show that femoral as well as carotid ultrasound may well be valuable. In particular, almost a fifth of patients with plaque had femoral lesions only.


Disclosure:

S. Croca,
None;

D. A. Isenberg,
None;

A. Rahman,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ultrasound-assessment-of-both-carotid-and-femoral-arteries-in-patients-with-systemic-lupus-erythematosus-increases-sensitivity-for-detecting-asymptomatic-atherosclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology